Found: 1
Select item for more details and to access through your institution.
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1).
- Published in:
- 2021
- By:
- Publication type:
- Letter